Exclusive offering with limited seating

Testosterone Therapy and Sexual Dysfunction – Demystifying the Hype with Science to Provide Cutting Edge Treatment for Your Patients

Testosterone therapy is one of the most controversial topics in medicine, yet multiple medical societies endorse its use, supported by level 1 evidence showing a variety of health benefits in men. This innovative and comprehensive course will focus on testosterone deficiency and its treatment in men and women and will also address several other sexual issues. Studies indicate that nearly 40% of men over the age of 45 have overtly low testosterone levels, yet education in this area is extremely limited. Similarly, there have been few educational opportunities to address sexual dysfunction in men and women. Approximately 40% of men and a similar percentage in women have one sexual dysfunction or another. Indeed, there have been several fascinating therapeutic advances in the treatment of sexual dysfunction in women that have received scant attention in other educational events.

The course is led by men’s health pioneer Abraham Morgentaler, MD, FACS whose research in the field transformed our understanding of the science of testosterone in men. Dr. Morgentaler has assembled as all-star faculty of thought leaders to address the most relevant issues and controversies, demystify the topic with science and clinical experience and provide an evidence-based approach to treatment. The course will also address management of several common sexual problems for men, including erectile dysfunction and Peyronie’s disease, and will also address several common sexual issues for women, including hypoactive sexual desire disorder. A clinical psychologist and sex therapist will explore non-medical strategies for managing couples with sexual complaints.

Engaging Sessions with Prominent Experts

Our best teachers and clinicians will cover these topics through:

  • Innovative lectures
  • Valuable case-based sessions
  • Live demonstrations
  • Question-and-answer panels
  • Interactive discussions

An Icon in Testosterone Therapy

Neil H. Baum, MD presented “Interviews with Icons: Abraham Morgentaler, MD, FACS, and Testosterone Therapy in Clinical Medicine” for the Grand Rounds in Urology audience in February 2023.

Program Highlights

  • The importance of testosterone in male health
  • Hormone replacement therapy in women
  • The ABCs of testosterone
  • Can testosterone be used in men with prostate cancer?
  • Testosterone and the risk of breast cancer in women
  • Reducing risks, including cardiovascular disease
  • Effective and safe interventions to preserve fertility
  • Is it low T or natural aging?
  • The who, when and why of testosterone replacement therapy
  • Advising patients on testosterone myths and facts
  • Current evidence regarding HRT in women
  • Addressing “hormonophobia”: What’s the truth?
  • Evidence-based solutions for improving male sexual problems
  • Diagnosis and treatment of Peyronie’s disease
  • Hypoactive sexual desire disorder and other common sexual issues for women
  • Real-world evidence – who’s a candidate for T therapy? Recent updates on society guidelines and recommendations
  • Management of complex cases
  • How to handle adverse effects from treatment (i.e., erythrocytosis, rise in PSA)
  • Common female sexual issues and their treatment
  • Non-medical strategies for managing couples with sexual complaints – expert advice from a clinical psychologist and sex therapist
  • Evaluation and cutting-edge treatment for ED
  • Medical management of transgenderism
  • Practical pearls from Dr. Morgentaler

Welcome from the Director

Testosterone therapy has been controversial since it first became available in the 1930s. Today, we know that not only do men with testosterone deficiency suffer from a variety of troubling sexual and non-sexual symptoms, but also that there are important health risks associated with untreated testosterone deficiency, including obesity, decreased bone mineral density and increased mortality.

It is a particularly exciting time to be discussing testosterone therapy, since the results of the large and long-awaited TRAVERSE trial have clarified several of the key issues that have troubled the field for decades. We now have level 1 evidence that testosterone therapy provides valuable benefits to men, and numerous medical societies have published guidelines endorsing the use of testosterone therapy.

Yet there remains a poor knowledge base among physicians and considerable misunderstanding of testosterone therapy, its benefits and its risks! There is confusion as to who is a candidate, how to make the diagnosis, how to treat and what the actual risks are, including cardiovascular and prostate cancer.

I have been researching and publishing on this topic for over 40 years, while gaining extensive clinical experience in my medical practice as the founder of the first comprehensive men’s health center in the US. My work has helped transform our understanding of the relationship between testosterone and prostate cancer, and it has been gratifying to see the field evolve as ideas once considered “dangerous” have now become mainstream as the implications of that research have been widely accepted.

I am delighted to be able to offer this course, addressing not only testosterone issues but also a number of sexual health problems affecting both men and women. These are common issues encountered by healthcare providers every day. The superb faculty and I will provide a comprehensive, evidence-based approach to these issues, combined with pearls from clinical experience, so that you will be able to return to your practice with improved comfort and confidence to effectively help your patients with testosterone deficiency and other sexual concerns.

We hope you will join us January 17-18, 2025, in Orlando, Florida, for an exciting weekend of learning.

Abraham Morgentaler, MD, FACS
Course Director


Register by Nov. 22, 2024 for discounted pricing!


This program is among the highest-rated Harvard Medical School CME courses. This course sold out in 2024; early registration is strongly recommended.


  • 15.75 AMA PRA Category 1 Credits
  • 15.75 ABIM MOC Points
  • 4.50 Risk Management Credits
  • AAFP Credits pending
  • Commensurate Credits from the Royal College of Physicians and Surgeons of Canada and the European Union of Medical Specialists


This special program provides education for:

  • Endocrinologists
  • Urologists
  • Family practice providers
  • Primary care providers
  • Geriatricians
  • Gynecologists
  • Psychiatrists
  • Psychologists
  • NPs
  • PAs
  • Other clinicians who treat low testosterone and male and female sexual health issues


Beth Israel Deaconess Medical Center